Detection of loss of heterozygosity in tumor and serum of melanoma patients
First Claim
Patent Images
1. A method of detecting melanoma in a patient comprising:
- a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of the LOH marker;
wherein the LOH of the marker is indicative of melanoma in the patient.
1 Assignment
0 Petitions
Accused Products
Abstract
A method is provided for assessing allelic losses on specific chromosomal regions in melanoma patents. The method relies on the evidence that free DNA may be released in the plasma/serum of cancer patients allowing the detection of DNA with LOH in the plasma/serum of cancer patients by analysis for microsatellite markers. The amount of and specific allelic loss allows a prognosis to be made regarding tumor diagnosis and progression, tumor metastasis, tumor recurrence, and mortality.
-
Citations
108 Claims
-
1. A method of detecting melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of the LOH marker;
wherein the LOH of the marker is indicative of melanoma in the patient.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 41, 42, 43, 44, 45, 46, 47, 48, 49)
-
-
10. A method of monitoring treatment of melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of the LOH marker;
wherein the LOH of the marker is indicative of the efficacy of the treatment in the patient.- View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18, 50, 51, 52, 53, 54, 55, 56, 57, 58)
-
-
19. A method of detecting subclinical melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of the LOH marker;
wherein the LOH of the marker is indicative of subclinical melanoma in the patient.- View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 59, 60, 61, 62, 63, 64, 65, 66, 67)
-
-
28. A method of prognosing melanoma in a melanoma patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of the LOH marker;
wherein an incease in the LOH of the marker is indicative of a poorer prognosis in the patient.- View Dependent Claims (29, 30, 31, 32, 33, 34, 35, 36, 68, 69, 70, 71, 72, 73, 74, 75, 76)
-
-
37. A method of detecting melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of two or more of the LOH markers;
wherein the LOH of the markers is indicative of melanoma in the patient.- View Dependent Claims (77, 78, 79, 80, 81, 82, 83, 84)
-
-
38. A method of monitoring treatment of melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S295; and
b) detecting the presence or absence of two or more of the LOH markers;
wherein the LOH of the markers is indicative of the efficacy of the treatment in the patient.- View Dependent Claims (85, 86, 87, 88, 89, 90, 91, 92)
-
-
39. A method of detecting subclinical melanoma in a patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of two or more of the LOH markers;
wherein the LOH of the markers is indicative of subclinical melanoma in the patient.- View Dependent Claims (93, 94, 95, 96, 97, 98, 99, 100)
-
-
40. A method of prognosing melanoma in a melanoma patient comprising:
-
a) performing a nucleic acid amplification reaction in a sample derived from acellular blood plasma or serum from the patient, wherein the amplification reaction is designed to amplify a loss of heterozygosity (LOH) marker from a locus selected from the group consisting of D1S214, D1S228, D3S1293, D6S264, D9S157, D9S161, S10S212, D10S216, and D11S925; and
b) detecting the presence or absence of two or more of the LOH markers;
wherein an increase in the LOH of the markers is indicative of a poorer prognosis in the patient.- View Dependent Claims (101, 102, 103, 104, 105, 106, 107, 108)
-
Specification